Section Arrow
Quote
FDMT.NASDAQ
- 4D Molecular Therapeutics
Quotes are at least 15-min delayed:2026/07/09 23:02 EDT
Regular Hours
Last
 12.89
-0.13 (-1.00%)
Day High 
13.3599 
Prev. Close
13.02 
1-M High
14 
Volume 
642.57K 
Bid
12.7
Ask
13.2
Day Low
12.6802 
Open
13.02 
1-M Low
8.37 
Market Cap 
680.64M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 12.52 
20-SMA 10.99 
50-SMA 10.01 
52-W High 14 
52-W Low 4.11 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.57/-4.52
Enterprise Value
696.46M
Balance Sheet
Book Value Per Share
8.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
85.21M
Operating Revenue Per Share
0.04
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VRAXVirax Biolabs Group Limited6.36+3.18+100.00%-- 
EVGNEvogene Ltd.0.5+0.0859+20.74%-- 
RXRXRecursion Pharmaceuticals3.76+0.04+1.08%-- 
IONSIonis Pharmaceuticals64.27-20.19-23.90%-- 
BBIOBridgeBio Pharma90.17+11.84+15.12%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.